内科理论与实践 ›› 2022, Vol. 17 ›› Issue (04): 353-355.doi: 10.16138/j.1673-6087.2022.04.017
徐娜娜, 吴涛(
), 寇明坤, 白海
收稿日期:2021-03-08
出版日期:2022-07-18
发布日期:2022-08-08
通讯作者:
吴涛
E-mail:wutaozhen@yeah.net
基金资助:
Received:2021-03-08
Online:2022-07-18
Published:2022-08-08
中图分类号:
徐娜娜, 吴涛, 寇明坤, 白海. ASXL1基因突变在急性髓系白血病中的研究进展[J]. 内科理论与实践, 2022, 17(04): 353-355.
| [1] |
Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel[J]. Blood, 2017, 129(4): 424-447.
doi: 10.1182/blood-2016-08-733196 URL |
| [2] |
Schuettengruber B, Bourbon HM, Di Croce L, et al. Genome regulation by polycomb and trithorax: 70 years and counting[J]. Cell, 2017, 171(1): 34-57.
doi: S0092-8674(17)30890-5 pmid: 28938122 |
| [3] |
Fujino T, Kitamura T. ASXL1 mutation in clonal hematopoiesis[J]. Exp Hematol, 2020, 83: 74-84.
doi: 10.1016/j.exphem.2020.01.002 URL |
| [4] |
Inoue D, Fujino T, Sheridan P, et al. A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies[J]. Leukemia, 2018, 32(6): 1327-1337.
doi: 10.1038/s41375-018-0083-3 URL |
| [5] |
Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB[J]. Nature, 2010, 465(7295): 243-247.
doi: 10.1038/nature08966 URL |
| [6] |
Hsu YC, Chiu YC, Lin CC, et al. The distinct biological implications of ASXL1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model[J]. J Hematol Oncol, 2017, 10(1): 1-15.
doi: 10.1186/s13045-016-0379-6 URL |
| [7] |
Zhang P, Chen Z, Li R, et al. Loss of ASXL1 in the bone marrow niche dysregulates hematopoietic stem and progenitor cell fates[J]. Cell Discov, 2018, 4: 4.
doi: 10.1038/s41421-017-0004-z pmid: 29423272 |
| [8] | 周柰岑, 李国辉, 秦炜炜, 等. 伴ASXL1基因突变的急性髓系白血病患者的临床特征及预后分析[J]. 中国实验血液学杂志, 2021, 29(6):1741-1745. |
| [9] |
Kakosaiou K, Panitsas F, Daraki A, et al. ASXL1 mutations in AML are associated with specific clinical and cytogenetic characteristics[J]. Leuk Lymphoma, 2018, 59(10): 2439-2446.
doi: 10.1080/10428194.2018.1433298 URL |
| [10] |
Kitamura T. ASXL1 mutations gain a function[J]. Blood, 2018, 131(3): 274-275.
doi: 10.1182/blood-2017-12-816595 pmid: 29348310 |
| [11] |
Prats-Martín C, Burillo-Sanz S, Morales-Camacho RM, et al. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype[J]. Cancer Med, 2020, 9(11): 3637-3646.
doi: 10.1002/cam4.2947 URL |
| [12] | 林云. 伴ASXL1基因突变成人初诊急性髓系白血病的临床特征及预后研究[D]. 福建医科大学, 2016. |
| [13] |
Alvarez Argote J, Dasanu CA. ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival[J]. Curr Med Res Opin, 2018, 34(5): 757-763.
doi: 10.1080/03007995.2016.1276896 URL |
| [14] |
Liu F, Gong M, Gao L, et al. RASSF1A hypermethylation is associated with ASXL1 mutation and indicates an adverse outcome in non-M3 acute myeloid leukemia[J]. Onco Targets Ther, 2017, 10: 4143-4151.
doi: 10.2147/OTT.S142528 URL |
| [15] |
Devillier R, Mansat-De Mas V, Gelsi-Boyer V, et al. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes[J]. Oncotarget, 2015, 6(10): 8388-8396.
doi: 10.18632/oncotarget.3460 pmid: 25860933 |
| [16] | 滕广帅, 王颖韶, 徐晶, 等. ASXL1突变的髓系肿瘤患者共突变基因谱及其临床意义[J]. 天津医药, 2018, 46(12): 1295-1299. |
| [17] |
Makishima H. Somatic SETBP1 mutations in myeloid neoplasms[J]. Int J Hematol, 2017, 105(6): 732-742.
doi: 10.1007/s12185-017-2241-1 pmid: 28447248 |
| [18] | 王双玲, 林建雄, 刘峰, 等. TET2在急性髓系白血病中的突变情况及其临床特征[J]. 中国实用医药, 2019, 14(31): 1-3. |
| [19] |
Bera R, Chiu MC, Huang YJ, et al. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia[J]. J Hematol Oncol, 2019, 12(1): 104-122.
doi: 10.1186/s13045-019-0789-3 URL |
| [20] |
Nagase R, Inoue D, Pastore A, et al. Expression of mutant ASXL1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation[J]. J Exp Med, 2018, 215(6): 1729-1747.
doi: 10.1084/jem.20171151 URL |
| [21] |
Carbuccia N, Trouplin V, Gelsi-Boyer V, et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias[J]. Leukemia, 2010, 24(2): 469-473.
doi: 10.1038/leu.2009.218 pmid: 19865112 |
| [22] | 胡晋君.TET2(rs2454206、rs12498609)及ASXL1(rs3746609) 单核苷酸多态性与MDS及其向AML转化的相关性研究[D]. 山西医科大学,2019. |
| [1] | 尹彦江, 罗治文, 陈晓, 张业繁, 黄振, 赵宏, 赵建军, 李智宇, 周健国, 蔡建强, 毕新宇. 肝内胆管癌病人肝脏手术切缘与预后的关系[J]. 外科理论与实践, 2022, 27(3): 221-228. |
| [2] | 杨崔燕, 王豪雨, 陈小松, 沈坤炜. 抑癌基因TP53突变状态与三阴性乳腺癌病人预后的研究[J]. 外科理论与实践, 2022, 27(05): 421-428. |
| [3] | 周易, 陈影, 陈尔真. 甲状腺激素对脓毒症脏器功能维护作用的研究进展[J]. 内科理论与实践, 2022, 17(05): 408-412. |
| [4] | 程威, 黄雨桦, 王剑, 李幼生. 影响癌性肠梗阻病人预后的多因素分析[J]. 外科理论与实践, 2022, 27(04): 340-345. |
| [5] | 蒋天依, 刘福佳, 程雯艳, 赵慧瑾, 沈杨. 重组人血小板生成素治疗急性髓系白血病化疗后血小板减少[J]. 内科理论与实践, 2022, 17(04): 283-288. |
| [6] | 郝旭, 王伟铭. 依靠肾活检确诊的以肾脏病变为主要表现的法布里病1例报告[J]. 诊断学理论与实践, 2022, 21(04): 527-529. |
| [7] | 陈敏, 车在前, 陈影, 马丽, 赵冰, 周伟君, 毛恩强, 陈尔真. 白细胞血小板比值早期评估脓毒症预后的临床研究[J]. 内科理论与实践, 2022, 17(03): 208-213. |
| [8] | 罗东凤, 游建华, 李啸扬, 李军民, 张赟翔. 不耐受强化化疗的初治老年急性髓系白血病患者诱导治疗疗效及安全性[J]. 内科理论与实践, 2022, 17(03): 220-226. |
| [9] | 李蕾, 袁菲, 王朝夫, 许海敏, 王婷. 101例壶腹部腺癌临床病理及预后因素分析[J]. 诊断学理论与实践, 2022, 21(03): 355-361. |
| [10] | 沐阳, 陈欣. 血浆降钙素原和C反应蛋白对多发伤病人预后评估的价值[J]. 外科理论与实践, 2021, 26(6): 532-536. |
| [11] | 符国新 王舒舒 何垚 宋晓萌 朱载瓯. 腮腺手术中应用美容切口与 Blair 切口比较的系统评价及 Meta 分析 [J]. 组织工程与重建外科杂志, 2021, 17(6): 532-. |
| [12] | 陈曦, 杜鹃. 多发性骨髓瘤预后风险的精准评估[J]. 诊断学理论与实践, 2021, 20(06): 522-528. |
| [13] | 冯国伟, 张晓娟, 郭睿, 关哲, 王越. 治疗前18F-FDG PET/CT显像对结外NK/T细胞淋巴瘤的预后判断价值[J]. 诊断学理论与实践, 2021, 20(06): 533-539. |
| [14] | 周璐, 雷航, 洪叶, 金爽, 董永勤, 王学锋, 蔡晓红. 一个新的ABO*A等位基因导致的AwB亚型及其分子机制研究[J]. 诊断学理论与实践, 2021, 20(06): 547-551. |
| [15] | 梁亚丽, 赵海港, 项广宇. 应激性高血糖比值预测急性缺血性脑卒中患者溶栓治疗后1年不良预后的价值[J]. 诊断学理论与实践, 2021, 20(06): 562-566. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
